Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rod Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert W. Chen, Tatyana Feldman, Andres Forero-Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, David J. Straus, Anas Younes, Keenan Fenton, Thomas John Manley, Gerald Engley, Joseph M. Connors
Institutions: The Barbara Ann Karmanos Cancer Institute, Stanford Cancer Institute, Mayo Clinic, Washington University in St. Louis, City Of Hope National Medical Center, Hackensack University Medical Center, University of Alabama at Birmingham, University of Rochester Medicine, University of Washington, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Princess Margaret Cancer Centre, BC Cancer Agency, Memorial Sloan Kettering Cancer Center, Seagen (United States)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2892373904